The evidence files, A–Z.
Browse 50 checked evidence files, start with a question, or request coverage when the name you heard is missing.
50 completed evidence files are public and linked below. Missing a name? Request coverage below. A request is not a recommendation or a promise to publish.
Start with what you want to understand
This is guided learning, not a treatment quiz. Choose a question to filter the completed evidence files; PepCurrent does not choose a peptide for you.
Completed evidence files · A–Z
All 50 are visible by default. The approval or regulatory boundary comes before the name; the short answer comes from the reviewed Library content.
Amycretin / zenagamtide
Amycretin—now called zenagamtide—puts GLP-1 and amylin activity into one investigational peptide. Early randomized studies report different weight and safety findings for the oral and injected programs, and phase 3 work is underway or planned. That is a serious development program, not FDA approval or proof of long-term benefit.
AOD-9604
The largest study in FDA's review enrolled 536 people and did not beat placebo on weight loss.
BPC-157
One 12-person uncontrolled study is the entire human musculoskeletal record identified in the cited review. PCAC recommended inclusion; FDA final action remains pending.
Bremelanotide / PT-141
One narrow FDA approval is real. Broad claims for men, postmenopausal women, and performance are not the approved use.
Cagrilintide / CagriSema
Defined cagrilintide and semaglutide study products have phase 3 evidence. The proposed fixed-dose product is submitted, not approved, and the results do not authenticate unrelated products.
Cathelicidin LL-37
LL-37 has human studies, but they are small and route-specific—mostly topical wound work. The largest venous-ulcer trial was negative in the full cohort. The boundary is that topical, intratumoral, or engineered oral-product findings do not validate generalized injectable immune, infection, recovery, or longevity claims.
CJC-1295 + Ipamorelin
Real GH/IGF-1 elevation, measured in people. Zero human trial of the actual stack. WADA-banned.
Dihexa
No administered-human evidence was identified; two central mechanism papers are retracted and a third carries a notice of concern.
Dulaglutide
Dulaglutide is the active ingredient in FDA-approved Trulicity. The reviewed label covers type 2 diabetes in adults and children 10 years and older, plus cardiovascular-risk reduction in defined adults with type 2 diabetes. It is not a general weight-loss approval, and it does not authenticate a compounded or unidentified product.
Elamipretide / Forzinity
A real accelerated approval for a narrow Barth syndrome population—not an anti-aging or general-energy approval.
Eloralintide
Eloralintide is a long-acting investigational amylin analog designed to favor the AMY1 receptor. Randomized phase 1 and 2 studies report weight and adverse-event findings, and phase 3 trials are registered. None of that yet establishes approval, long-term benefit, superior clinical outcomes, or combination safety.
Emideltide / DSIP
Small intravenous studies from the 1980s exist, but FDA calls the insomnia evidence inconclusive and preliminary.
Epitalon
One narrow human biomarker study does not demonstrate insomnia treatment, age reversal, or longer life.
Exenatide
Exenatide has FDA-approved type 2 diabetes uses, but “exenatide” does not describe one interchangeable product. FDA records show the branded immediate- and extended-release products as discontinued while a generic application has Prescription status. Evidence from one release form does not automatically transfer to another—or to a general weight-loss claim.
Follistatin-344
The human studies people cite for Follistatin-344 are not trials of an FS344 protein injection. They are very small open-label gene-transfer studies in neuromuscular disease. Follistatin-344 is a precursor and transgene identity, not one interchangeable finished product; FDA's orphan record says the cited AAV-delivered product is not approved for that indication.
GHK-Cu (Copper Peptide)
Legal cream with modest data. The injected version people sell has zero human trials.
GHRP-2
GHRP-2 can raise growth hormone and food intake in small human studies. A five-day study also found the hormone response fading and no mean IGF-I increase. Hormone levels and a buffet meal are real endpoints; they are not evidence of muscle, fat-loss, recovery, sleep, performance, or long-term safety benefits.
GHRP-6
Small human studies show that GHRP-6 can change growth hormone, ACTH, cortisol, stage-2 sleep, glucose, and insulin under specific conditions. That is a list of measured signals, not proof of better sleep, more muscle, fat loss, recovery, or long-term safety. FDA also flags compounding-specific immune and metabolic concerns.
Gonadorelin
Gonadorelin has real human fertility and hormone evidence in selected deficiency populations. The seam is specificity: those findings depend on the population and the pulsatile regimen studied. FDA records historical diagnostic-use approvals for Factrel injection and the Lutrepulse pulsatile-pump kit; that does not establish current availability or authenticate veterinary, warning-letter, or unidentified products.
Hexarelin
Hexarelin has small human studies showing short-term hormone and cardiac-performance effects, plus a narrow 16-week endocrine follow-up. PepCurrent found no controlled evidence for muscle, fat loss, recovery, anti-aging, or patient-important heart benefit. FDA's 2025 Darmerica warning letter also records an ingredient-listing mismatch for one Hexarelin acetate entry.
Humanin
Humanin appears in human research—as something measured, not as a treatment people received. PepCurrent found biomarker and physiology studies, plus cell and animal work, but no human administration trial or FDA-approved Humanin product. Measuring what the body makes is not evidence that giving the peptide treats anything.
Ibutamoren / MK-677
Human trials show endocrine target engagement and selected body-composition changes without consistent clinical benefit; important safety signals remain.
IGF-1 LR3
Animal, cell, and product-analysis records do not establish human muscle, recovery, performance, cognition, anti-aging, or safety claims.
Kisspeptin-10
Kisspeptin-10 can move LH and related reproductive hormones in small human physiology studies. That is a measured short-term hormone response, not proof that it treats infertility, sustained low testosterone, or libido. FDA has not approved Kisspeptin-10 as a drug, and no final bulks-list action was identified.
KPV
Preclinical anti-inflammatory findings; FDA identified no human exposure data through any route.
Liraglutide
Large weight and cardiovascular trials make it foundational—not interchangeable with every product bearing its name.
Lixisenatide
Lixisenatide has randomized human evidence and an FDA-approved type 2 diabetes use. The product story is less simple: FDA's Purple Book marks the single-ingredient Adlyxin presentations discontinued, while lixisenatide remains part of the approved Soliqua combination. Approved ingredient, discontinued presentation, and current combination are three different facts.
Maridebart cafraglutide / MariTide
MariTide—maridebart cafraglutide, formerly AMG 133—is an investigational antibody carrying two GLP-1-like peptides. It has published randomized phase 2 obesity evidence and an active phase 3 program. Phase 3 enrollment is not FDA approval, a final safety record, or proof that a product outside the trial is the studied drug.
Mazdutide
Positive phase 3 evidence in China does not become U.S. approval or online-product equivalence.
Mecasermin
Mecasermin is recombinant human IGF-1 and the active ingredient in FDA-approved INCRELEX. The approval is for growth failure in tightly defined pediatric severe-primary-IGF-1-deficiency populations. Mecasermin is not IGF-1 LR3, and a pediatric growth record does not become evidence for adult muscle, performance, recovery, or anti-aging claims.
Melanotan II
Visible tanning is not proof of safety. FDA records describe an unapproved substance and serious safety signals.
MOTS-c
Human studies measure the body's own MOTS-c. FDA identified no studies administering it to people.
Oxytocin
Approved injectable obstetric uses do not establish intranasal bonding, relationship, sexual-wellness, or autism treatment claims.
PEG-MGF
PEG-MGF is not one clearly defined molecule. The name leaves open the base peptide, PEG size, attachment site, linker, and impurity profile, so it cannot stand in for endogenous IGF-1Ec or every MGF peptide. FDA says it found no human-exposure data for PEG-MGF drug products; PepCurrent's exact ClinicalTrials.gov search found zero studies and no original human-administration paper.
Pemvidutide
Pemvidutide has phase 2 human signals for MASH resolution, liver fat, biomarkers, and weight in defined populations. It remains investigational. Breakthrough Therapy designation can speed development; it does not create an approved indication, long-term benefit record, or complete safety profile.
Petrelintide
Petrelintide, also called ZP8396, is an investigational long-acting amylin analog. Published phase 1 studies provide human data; the completed phase 2 result is still a sponsor conference report, and phase 3 is planned. Planned and presented are not the same as approved, peer-reviewed, or proven long term.
Pramlintide
Pramlintide is a lab-made analog of human amylin. Symlin was FDA approved for defined people with type 1 or type 2 diabetes using mealtime insulin, but FDA's current exact-substance record lists every Symlin product as discontinued. The approval was not for general obesity, and pramlintide is not interchangeable with every newer amylin drug.
Retatrutide / “Reta”
A phase 3 diabetes trial is published; TRIUMPH-1 obesity is completed with no registry results posted. Retatrutide is still investigational.
Selank
Small active-comparator and adjunctive studies exist, but no modern placebo-controlled efficacy record or complete safety profile was identified.
Semaglutide
Strong human evidence for specific approved products. An unrelated online vial does not inherit that evidence.
Semax
Small intranasal studies exist. They do not establish benefit or safety for the injectable products promoted online.
Sermorelin
Historical Geref approval is real. It is not a current anti-aging approval or proof that a different product is equivalent.
Setmelanotide
Setmelanotide is the active peptide in FDA-approved IMCIVREE. Its March 2026 label covers weight reduction in a short list of acquired hypothalamic and genetically defined obesity populations. It is not a general-obesity approval, and it does not authenticate a compounded or unidentified product.
Somatropin / HGH
Approved replacement uses do not establish general anti-aging, bodybuilding, recovery, or performance benefits.
Survodutide
Survodutide has published phase 3 placebo-controlled obesity and liver-fat results. That is substantial human evidence, and the original papers still call it investigational. The trials do not create FDA approval, prove superiority to another medicine, or authenticate a different product.
TB-500 (Thymosin Beta-4)
The “Wolverine peptide” claim still outruns the human evidence. PCAC recommended inclusion; FDA final action remains pending.
Tesamorelin
A real FDA approval for excess abdominal fat in adults with HIV and lipodystrophy—not general weight loss.
Thymosin alpha-1
Human research exists, but “immune boost” overstates it; a 1,106-person sepsis trial found no mortality benefit.
Tirzepatide (Mounjaro / Zepbound)
The control group for this whole library: 2,500-person RCTs, ~20% weight loss, FDA-approved.
VIP / aviptadil
Aviptadil is a lab-made version of the body's 28-amino-acid vasoactive intestinal peptide. The larger TESICO randomized trial did not improve its primary 90-day outcome in COVID-19 hypoxemic respiratory failure. Smaller studies cannot turn that into broad effectiveness, approval, or interchangeability across routes and products.
Missing the one you heard about?
Send the name, nickname, or claim shorthand. Requests guide coverage; they do not create a recommendation or publication promise.
Put it on our research radar.
PepCurrent does not sell, rank, prescribe, or source compounds. This field is only a way to tell the editorial desk what readers are encountering.
Read the evidence
Four short guides for the distinctions underneath almost every peptide claim.
Approved, investigational, compounded, or “research use only”?
Four labels that answer four different questions.
Read the guide → FIELD GUIDE 02How to read a peptide study without getting snowed
Five checks for the next viral screenshot.
Read the guide → FIELD GUIDE 03Why the same ingredient name is not the same product
The fastest way to spot a product-identity leap.
Read the guide → FIELD GUIDE 04What does an FDA peptide vote actually change?
Staff analysis, committee advice, final action, and product identity.
Read the guide →